Palivizumab Synagis®
The SHIKARI® Palivizumab portfolio separates quantitative free-drug measurement from quantitative and qualitative anti-palivizumab antibody research.
Why Palivizumab is relevant to biological-drug monitoring research
Palivizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Palivizumab is a humanised IgG1κ monoclonal antibody directed against the fusion (F) protein of respiratory syncytial virus (RSV), inhibiting viral fusion and entry. Source ↗
Approved Indications
EMA-authorised use is prevention of serious RSV lower-respiratory-tract disease in defined high-risk paediatric groups. EMA source ↗
Monthly-Dose Trough Exposure
At 15 mg/kg monthly dosing, regulatory data show progressive trough accumulation across successive injections:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Three verified Palivizumab research assays
Ligand-binding ELISA for quantitative analysis of free palivizumab in human serum or plasma.
Quantitative ELISA for anti-palivizumab antibodies with an assay-specific confirmation workflow.
Qualitative ELISA for reactive or non-reactive assessment of anti-palivizumab antibodies using assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-PAL | PAL-FD-SYN | Quantitative | Free palivizumab | Human serum / plasma | 10 µL | 70 min | LOD 3 ng/mL; LOQ 3 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATPAL | PAL-QNS-SYN | Quantitative | Anti-palivizumab antibodies | Human serum / plasma | 5 µL | 140 min | LOD 18.75 ng/mL; LOQ 31.25 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATPAL | PAL-QLS-SYN | Qualitative | Anti-palivizumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Palivizumab Literature and Product-Use Records
Planning a Palivizumab research study?
Matrix Biotek can help identify the appropriate Palivizumab assay and prepare regional quotation and delivery information.